Erratum to: Sorafenib-Associated Facial Acneiform Eruption

Philip R. Cohen

To view enhanced content go to www.dermtherapy-open.com
Received: November 3, 2014 / Published online: January 24, 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Erratum to: Dermatol Ther (Heidelb) (2014) 5(1)
DOI 10.1007/s13555-014-0067-9

The author of the above-mentioned paper noticed some errors subsequent to publication and would like to make the following correction.

On page 6 there is to be a change to the labelling of **Table 2** footnotes. “**Table 2** Characteristics of patients with sorafenib-

associated facial acneiform facial eruptions” is to be replaced with the following:

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

The online version of the original article can be found under doi:[10.1007/s13555-014-0067-9](https://doi.org/10.1007/s13555-014-0067-9).

P. R. Cohen (✉)
Division of Dermatology, University of California
San Diego, 10991 Twinleaf Court, Twinleaf Court,
California 92131-3643, USA
e-mail: mitehead@gmail.com

Table 2 Characteristics of patients with sorafenib-associated facial acneiform facial eruptions

Case [Ref.]	1 [37]	2 [38] C1	3 [39]	4 [38] C2	5 CR
Age (years)	42	51	52	65	79
Race	NS	White	White	White	Asian
Sex	Female	Male	Male	Male	Male
Ca	LEH	mRCC	mRC	mRCC	HCC
FAL	+	^b	+	^d	^f
OSAL	Trunk (upper)	Arms, axillae, back (upper), chest (upper)	Genital area, neck, scalp	–	–
Symptoms	–	Burning sensation, oiliness (increased), pruritus	Pain	Oiliness (increased)	–
Lesion morph	Papules, pustules	Open comedones = closed comedones (Ca-L)	Papules, pustules	Open comedones = closed comedones (Ca-L)	Open comedones > closed comedones (Ca-L)
Soraf dose	400 mg BID × 4 weeks, then 800 mg BID	400 mg BID	600 mg QD	400 mg BID	400 mg BID
Onset ^a	4.1	6	4	8	1.3
OSCAE	NS	NS	Alopecia, HFSCR, SFFH, Sp-1	NS	Alopecia, HFSCR, ISK, SD-LE, xerosis
Treatment	Cleared 2 weeks after Soraf dose lowered to 400 mg BID	70% improvement after BP × 2 months	Improvement after oral tetracycline and topical: BP, EES, Flu, and Met	Tret 0.05%	Clin, Tret 0.025%

Table 2 continued

Case [Ref.]	1 [37]	2 [38] CI	3 [39]	4 [38] C2	5 CR
Comment	Pt died 2 months after lowering dose of Soraf from cancer prog	^c	Soraf stopped for surgery; ACE reappeared when restarted soraf	Exposure to Agent Orange in Vietnam ^e	Lesions slowly resolving with topical therapy after stop Soraf
	<p>ACE acneiform eruption, <i>BID</i> twice daily, <i>BP</i> benzoyl peroxide, <i>Ca</i> cancer, <i>Ca-L</i> chloracne-like, <i>C</i> case, <i>Clin</i> clindamycin 1% solution twice daily, <i>CR</i> current report, <i>EES</i> erythromycin, <i>FAL</i> facial acneiform lesions, <i>Flu</i> fluocinonide cream, <i>HCC</i> hepatocellular carcinoma, <i>HFSR</i> hand–foot skin reaction, <i>ISK</i> inflamed seborrheic keratosis, <i>LEH</i> liver epithelioid hemangioendothelioma, <i>Met</i> metronidazole, <i>mRC</i> metastatic renal carcinoma, <i>mRCC</i> metastatic renal cell carcinoma, <i>NS</i> not stated, <i>OSAL</i> other sites of acneiform lesions, <i>OSCAE</i> other sorafenib-associated cutaneous adverse events, <i>prog</i> progression, <i>Pt</i> patient, <i>QD</i> daily, <i>SD-LE</i> seborrheic dermatitis-like eruption, <i>SFFH</i> spiny filiform follicular hyperkeratosis, <i>soraf</i> sorafenib, <i>Sp-I</i> sandpaper-like skin texture, <i>Tret</i> 0.025% tretinoin 0.025% cream each evening, <i>Tret</i> 0.05% tretinoin 0.05% cream each evening, + present, – absent</p> <p>^a Number of weeks on sorafenib prior to appearance of acneiform eruption</p> <p>^b The facial acneiform lesions were located on bilateral malar cheeks and postauricular areas</p> <p>^c A skin biopsy of an acneiform lesion showed milia-like cyst with a sparse lymphocytic inflammatory dermal infiltrate</p> <p>^d The facial acneiform lesions were located on the nose and bilateral malar cheeks, temples and postauricular areas</p> <p>^e The patient did not return for follow up examination</p> <p>^f The facial acneiform lesions were located on bilateral malar cheeks, preauricular areas, ears and postauricular areas</p>				